Mike Doustdar

For some, probably yes.

For some, probably yes.

Others will prefer to have a weekly product.

Is it more important that Pfizer doesn't buy it than Novo does buy it?

Because that's another thing I hear as well.

My focus is on Novo Nordisk.

The way I see this is there's a company for sale, there's a buyer and a seller, and basically one of the buyers doesn't like the price, and the other one does.

My job is to make sure I look at what we need, and we would very much benefit from Matt Serra's assets, and we put the right price up there for our price.

What's the right price?

Could you go higher?

The current price in the market has been addressed by Matt Serra's shareholders, and then we'll see where this goes.

Do you think Pfizer comes back?

I have no idea.

You have no idea.

But if they do, will you go higher?

How important is this asset?

I'm not going to make an announcement today on how I'm going to treat this.

How do you make sure you don't overpay for this asset?

By having actually looked very deeply into the data.

As I mentioned, we know this company very well.